Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05, while State Street SPDR S&P Biotech ETF trades at $159.67. Which is the better fit depends on your goals.
| VEA | XBI | |
|---|---|---|
52-Week High | $73.79 | $169.55 |
52-Week Low | $58.90 | $93.43 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VEA trades at $73.46, down 0.41% on the day, with a bullish technical outlook supported by moving averages. The ETF recently hit a 52-week high of $74.04, indicating strong momentum. Institutional interest is growing, with multiple firms increasing positions in Q2 2026. VEA offers exposure to developed international markets with a low 0.03% expense ratio, making it a cost-effective diversification tool compared to broader international or emerging market ETFs.
The outlook remains positive given institutional accumulation and technical strength, though risks include currency fluctuations and global economic sensitivity. VEA's focus on developed markets provides stability versus emerging markets, but investors should monitor international economic trends that could impact performance.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
